Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Morning Guys, couldn"t agree more about Amplivant, or the reason for delays. The point is we are arriving at the place we want to be, IMHO at the right time, and have surrounded ourselves with the finest and best minds in the immuno oncology Industry.
Shame Botski is not attending tomorrow night, unfortunately nor can I, but wouldn"t it be good of Scancell if they recorded the event and showed it on the Scancell Website.? One for the future perhaps.
RayP/RW - yes it's the breadth and complexity of Scancell's science together with Prof. Lindy's thirst to make improvements that explains why the Scancell project can be perceived as progressing so slowly. WF - glad you can be so relaxed about the long wait - some of us older ones don't want to run out of time LOL. So I'm somewhat impatient myself with the SP at this level. ATB.
If Lindy can see an improvement that she thinks needs to be made, she goes ahead and makes it.
So we see in Moditope's case she saw that the addition of amplivant to the 3 targets in the vaccine would make a marked improvement. From memory the improvement was from 70% to 100% in the survival of mice.
Now this particular improvement must have proved to be tricky since the delay was of the order of 18 months (again from memory).
I'm making a guess here but maybe the difficulty was joining amplivant with the 3 targets in the most effective way i.e where is the best place to join the 2 molecular structures to achieve maximum improvement.
https://www.isa-pharma.com/technology/amplivant-technology/
"ISA’s AMPLIVANT® technology comprises a proprietary and synthetic Toll-Like Receptor (TLR)1/2 ligand with enhanced immunostimulatory activity that can be coupled to the peptide in the standard SLP® manufacturing process. Long peptide-AMPLIVANT® conjugate immunotherapeutics allow lower dosing at higher efficacy through better dendritic cell antigen processing and presentation as well as enhanced T cell priming."
So amplivant provides
1) Lower dosing
2) higher efficacy through better dendritic cell antigen processing and presentation
3) enhanced T cell priming (activation)
This last effect is the one that most interests me - Enhanced T Cell priming
Maybe it is this that gives the extra boost to Moditope and is the real cause for the increase in survival.
Initially I thought that TCell activation was binary - i.e. it was either activated or not. However Lindy states that when the Moditope activated TCells interact with the tumour cell they become further activated. This kind of supports a level of activation rather than a binary state.
So, going back to activation of the TCells by the APC - does amplivant give a higher level of activation to an individual TCell compared to that achieved without amplivant present?
I share the frustration at the length of time things take, but when you look at the amount of time and fine tuning needed to get Moditope ready for the clinic, five or six years isn't that long for something potentially so revolutionary. Imagine the difference between Moditope working and looking quite good, as opposed to working stunningly because it has been properly prepared. A year or two is worth the wait for the right outcome imo.
D'oh
Indeed inanaco and Chelsea.
Almost six years after the 2013 Scancell investor update , some of which I understood, and Moditope news, the now even more spectacular SCIB1 trial results and welcome huge checkpoint inhibitor advances by others, I can't help wondering about what might have been , in terms of delay: getting Scancell products to many thousands of patients .
Why such delay?
I wouldnt mind but nearly half a billion Euros worth of ""thinks will", lol.
including a cell-penetrating peptide the biotech thinks will promote the efficient cross presentation of epitopes to cytotoxic T cells.
"thinks will"
Scancell ... does